Celcuity Inc (CELC): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Brandmark of Celcuity Corp (CELC)

Celcuity Inc. relies on a streamlined express delivery system for biosamples to laboratories. The company's current EV/EBITDA multiple reflects a valuation trend where 0.00 is the current figure. AI-powered CELx robotic systems eliminate human error during cell analysis. Stable demand for diagnostics renders the business insensitive to economic crises.

Celcuity Corp - CELC EV/EBITDA Multiple (period 11/23/2025 - 11/10/2026)

CELC (celcuity.com): analytical breakdowns and indicator data

- current price and projected stock value:
Stock Price Celcuity Corp|CELC - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Celcuity Therapeutics|CELC - Business Value
- book value of equity indicators:
Book Value per Share Celcuity|CELC - Book Capitalization|Market Value to Book Value Ratio celcuity.com|CELC - Aggregate Company Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Celcuity Inc.|CELC - Long-Term Liabilities to Capital|Short-Term Debt to Equity Celcuity|CELC - Company Total Debt Obligations|Debts to Book Capitalization Celcuity Therapeutics|CELC - Long-Term Debt Volume|Company Short-Term Debt Celcuity|Quick Ratio celcuity.com
- financial results and valuation multiples details:
CELC - Net Income|Projected Future Earnings Celcuity Inc.|CELC - Market Cap to Earnings|Future Price to Earnings Celcuity Inc.|CELC - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Celcuity Therapeutics|CELC - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Celcuity|CELC - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth celcuity.com|CELC - Expected net earnings per share growth this year|Expected earnings per share growth for next year Celcuity Inc.
Comprehensive company analysis:Celcuity Corp CELC
Manufactured products of Celcuity

This ratio correlates the total enterprise value, including net debt, with operating profit before taxes and depreciation, determining the payback period for all assets. By analyzing the EV/EBITDA multiple of Celcuity Inc. (CELC), an investor can assess the market value of Celcuity Inc. relative to its ability to generate cash flow against the costs of developing oncology drugs and implementing diagnostic systems.

Analysis of competing companies

EV/EBITDA Multiple CAI (Caris)|EV/EBITDA Multiple Guardant Corp GH|VCYT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GRAL (grail.com) - Enterprise Value to Operating Income Before Depreciation|MYGN: EV/EBITDA Multiple|Castle Biosciences Inc (CSTL) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Burning Rock Biotech Ltd.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization VNRX|Enterprise Value to EBITDA Ratio BDSX (Biodesix, Inc.)|PRPO - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Check-Cap CHEK|Total Company Value to Operating Income Before Depreciation Ratio mainzbiomed.com (MYNZ)|OncoCyte Corp. - EV/EBITDA Multiple